Clinical Application of Zanubrutinib in B-Cell Lymphoma --Review.
10.19746/j.cnki.issn.1009-2137.2022.03.049
- Author:
Xiao TANG
1
;
Wen-Rong ZOU
2
;
Peng PENG
1
;
Yang-Lyu BAI
1
Author Information
1. Department of Hematology, Sichuan Mianyang 404 Hospital, Mianyang 621000, Sichuan Province, China.
2. Department of Hematology, Sichuan Mianyang 404 Hospital, Mianyang 621000, Sichuan Province, China,E-mail: 13908114558@163.com.
- Publication Type:Review
- Keywords:
B-cell lymphoma;
BTK;
targeted therapy;
zanubrutinib
- MeSH:
Humans;
Lymphoma, B-Cell/drug therapy*;
Piperidines/therapeutic use*;
Protein Kinase Inhibitors/therapeutic use*;
Pyrazoles/therapeutic use*;
Pyrimidines/therapeutic use*
- From:
Journal of Experimental Hematology
2022;30(3):965-969
- CountryChina
- Language:Chinese
-
Abstract:
Zanubrutinib is a highly selective second-generation BTK inhibitor developed in China and first approved by the U.S. Food and Drug Administration (FDA) as a novel antineoplastic drug. In recent years, with the birth of molecularly targeted drugs, the treatment of B-cell lymphoma have entered the era of targeted therapy, and immunotherapy has been widely accepted. Especially in some relapsed and refractory lymphomas, zanubrutinib has shown deep and sustained remissions and a favorable safety, which lays a foundation for precision therapy. In this review the clinical application and new progress for zanubrutinib in B-cell lymphoma was summarized briefly.
